HMN 1152

Drug Profile

HMN 1152

Alternative Names: H 1152

Latest Information Update: 01 May 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nippon Shinyaku; Nonindustrial source
  • Class Small molecules; Vasodilators
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cerebral vasospasm

Most Recent Events

  • 18 Feb 1999 Preclinical development for Cerebral vasospasm in Japan (Unknown route)
  • 13 Aug 1998 Preclinical development for Vascular disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top